Last updated 6 days ago
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
810 patients around the world
Available in Argentina, United States, Spain, Brazil
Bristol-Myers Squibb
15Research sites
810Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Recruiting
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
Sanatorio Chivilcoy
Swiss Medical Center Barrio Parque - CABA
Recruiting
Clínica de Nefrología Urología y Enfermedades Cardiovasculares - Santa Fe
Recruiting
Hospital Privado de Rosario - Santa Fe
Recruiting
Hospital Privado de Córdoba
Recruiting
Hospital Mãe de Deus - Porto Alegre
Recruiting
Instituto Joinvilense de Hematologia e Oncologia (CEPEVILLE)
Recruiting
Hospital Amaral Carvalho
Recruiting
StudySuccessor-1
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05519085
